GNMSF - 3 Things In Biotech July 30: Europe News Continues To Dominate
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research.
Janssen headlines myeloma therapy in Europe
Company: Johnson & Johnson (JNJ) and Genmab (OTCPK:GNMSF)
Therapy: Daratumumab
Disease: Multiple myeloma
News: GNMSF announced that the CHMP has adopted a positive opinion on the expanded approval for daratumumab to include first-line treatment when used in combination with bortezomib, melphalan, and prednisone (the VMP regimen) in patients who cannot undergo a stem cell